RhumbLine Advisers
EDIT icon

RhumbLine Advisers’s Editas Medicine EDIT Stock Holding History

RhumbLine Advisers’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380K Buy
117,417
+10,217
+10% +$29.9K ﹤0.01% 2928
2026
Q1 		$265K Sell
107,200
-2,105
-2% -$4.46K ﹤0.01% 2975
2025
Q4 		$224K Sell
109,305
-13,221
-11% -$38.2K ﹤0.01% 3127
2025
Q3 		$425K Sell
122,526
-4,273
-3% -$11.9K ﹤0.01% 2805
2025
Q2 		$279K Buy
126,799
+2,949
+2% +$4.83K ﹤0.01% 3036
2025
Q1 		$144K Sell
123,850
-16,867
-12% -$24.8K ﹤0.01% 3275
2024
Q4 		$179K Sell
140,717
-1,158
-0.8% -$2.95K ﹤0.01% 3253
2024
Q3 		$484K Buy
141,875
+3,889
+3% +$16.9K ﹤0.01% 2719
2024
Q2 		$644K Buy
137,986
+3,862
+3% +$21.8K ﹤0.01% 2487
2024
Q1 		$995K Buy
134,124
+2,738
+2% +$22.8K ﹤0.01% 2248
2023
Q4 		$1.33M Sell
131,386
-33
-0% -$290 ﹤0.01% 2117
2023
Q3 		$1.03M Buy
131,419
+14,360
+12% +$123K ﹤0.01% 2195
2023
Q2 		$963K Buy
117,059
+5,642
+5% +$49.2K ﹤0.01% 2307
2023
Q1 		$808K Sell
111,417
-71
-0.1% -$631 ﹤0.01% 2226
2022
Q4 		$989K Buy
111,488
+2,881
+3% +$31.6K ﹤0.01% 2133
2022
Q3 		$1.33M Buy
108,607
+7,354
+7% +$115K ﹤0.01% 1988
2022
Q2 		$1.2M Buy
101,253
+28,708
+40% +$385K ﹤0.01% 2053
2022
Q1 		$1.38M Buy
72,545
+576
+0.8% +$10.7K ﹤0.01% 1994
2021
Q4 		$1.91M Sell
71,969
-1,902
-3% -$65.5K ﹤0.01% 1913
2021
Q3 		$3.04M Buy
73,871
+1,681
+2% +$92.1K ﹤0.01% 1656
2021
Q2 		$4.09M Sell
72,190
-3,217
-4% -$119K 0.01% 1526
2021
Q1 		$3.17M Sell
75,407
-4,334
-5% -$247K ﹤0.01% 1661
2020
Q4 		$5.59M Buy
79,741
+5,322
+7% +$219K 0.01% 1294
2020
Q3 		$2.09M Sell
74,419
-11,847
-14% -$386K ﹤0.01% 1662
2020
Q2 		$2.55M Buy
86,266
+12,202
+16% +$319K ﹤0.01% 1591
2020
Q1 		$1.47M Buy
74,064
+2,191
+3% +$55.3K ﹤0.01% 1710
2019
Q4 		$2.13M Buy
71,873
+6,114
+9% +$153K ﹤0.01% 1770
2019
Q3 		$1.5M Sell
65,759
-93
-0.1% -$2.3K ﹤0.01% 1866
2019
Q2 		$1.63M Buy
65,852
+5,316
+9% +$127K ﹤0.01% 1852
2019
Q1 		$1.48M Sell
60,536
-496
-0.8% -$11.2K ﹤0.01% 1862
2018
Q4 		$1.39M Buy
61,032
+20,080
+49% +$546K ﹤0.01% 1853
2018
Q3 		$1.3M Sell
40,952
-2,950
-7% -$95.3K ﹤0.01% 1875
2018
Q2 		$1.57M Buy
43,902
+9,343
+27% +$331K ﹤0.01% 1804
2018
Q1 		$1.15M Buy
34,559
+1,150
+3% +$41K ﹤0.01% 1879
2017
Q4 		$1.03M Hold
33,409
– – ﹤0.01% 1934
2017
Q3 		$802K Buy
33,409
+721
+2% +$13.7K ﹤0.01% 2086
2017
Q2 		$549K Buy
+32,688
New +$589K ﹤0.01% 2245

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

RhumbLine Advisers's EDIT Position: Q2 2026 in Review

RhumbLine Advisers increased its Editas Medicine (EDIT) stake by 9.5% in Q2 2026, buying an estimated $29.9K and bringing the position to 117,417 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #2928.

RhumbLine Advisers first reported a position in EDIT in Q2 2017 and has held it in 37 quarters since. The position peaked at $5.59M in Q4 2020. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • RhumbLine Advisers held 117,417 shares of Editas Medicine worth $380K as of Q2 2026.
  • RhumbLine Advisers bought 10,217 Editas Medicine shares in Q2 2026, an estimated $29.9K.
  • Editas Medicine made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2928 holding.
  • RhumbLine Advisers first reported a position in Editas Medicine in Q2 2017 and has held it in 37 quarters since.
  • RhumbLine Advisers's Editas Medicine position peaked at $5.59M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.